AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30277639 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVE-PC chemotherapy followed by response evaluation
Number of subjects: 96
Study 30277639 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVE-PC chemotherapy
Number of subjects: 96
Study 30277639 — intervention group
Group type: COMPARATOR
Intervention: Involved field radiotherapy (IFRT) or no further therapy for RERs with CR
Number of subjects: 96
Study 28855976 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxytyrosol (HT) 15 mg/day for 3 weeks
Number of subjects: 0
Study 26547357 — intervention group
Group type: EXPERIMENTAL
Intervention: Vericiguat 10 mg
Number of subjects: 456
Study 26547357 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled vericiguat groups (1.25 mg, 2.5 mg, 5 mg, 10 mg)
Number of subjects: 456
Study 26547357 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 456
Study 26547357 — intervention group
Group type: EXPERIMENTAL
Intervention: Vericiguat (various doses)
Number of subjects: 456
Study 23568622 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-carbamimidoyl-L-proline (CLP)
Number of subjects: 126
Study 23568622 — intervention group
Group type: COMPARATOR
Intervention: Placebo lotion
Number of subjects: 126
Study 20232386 — intervention group
Group type: EXPERIMENTAL
Intervention: Red meat consumption
Number of subjects: 99579
Study 20232386 — intervention group
Group type: EXPERIMENTAL
Intervention: Processed meat consumption
Number of subjects: 99579
Study 20232386 — intervention group
Group type: EXPERIMENTAL
Intervention: High-temperature cooking methods
Number of subjects: 99579
Study 20232386 — intervention group
Group type: EXPERIMENTAL
Intervention: Level of meat doneness
Number of subjects: 99579
Study 20232386 — intervention group
Group type: EXPERIMENTAL
Intervention: Intake of specific meat mutagens (MeIQx, DiMeIQx, PhIP, B(a)P)
Number of subjects: 99579
Study 20232386 — intervention group
Group type: EXPERIMENTAL
Intervention: Heme iron intake
Number of subjects: 99579
Study 19062477 — intervention group
Group type: EXPERIMENTAL
Intervention: Manix 600 mg for 13 weeks
Number of subjects: 55
Study 19062477 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E 1000 IU for 13 weeks
Number of subjects: 55
Study 19062477 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 55
Study 16906045 — intervention group
Group type: EXPERIMENTAL
Intervention: 1/Scr
Number of subjects: 148
Study 16906045 — intervention group
Group type: EXPERIMENTAL
Intervention: Cockcroft‐Gault
Number of subjects: 148
Study 16906045 — intervention group
Group type: EXPERIMENTAL
Intervention: MDRD
Number of subjects: 148
Study 16906045 — intervention group
Group type: EXPERIMENTAL
Intervention: Nankivell
Number of subjects: 148
Study 15646163 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of the effects of smoking
Number of subjects: 3360
Study 15646163 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking prevalence
Number of subjects: 3360
Study 11237920 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy
Number of subjects: 25
Study 11237920 — intervention group
Group type: EXPERIMENTAL
Intervention: Needling revision
Number of subjects: 25
Study 11237920 — intervention group
Group type: COMPARATOR
Intervention: Control (unoperated eye)
Number of subjects: 25
Study 11237920 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 25
Study 9386082 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) - 10 mg infused in 500 mL of normal saline
Number of subjects: 101
Study 9386082 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (AP) - High-dose: 280 mg loading dose, 280 mg in CPB prime solution, 70 mg/h for 6 hours
Number of subjects: 101
Study 9386082 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P) - Control group for TA
Number of subjects: 101
Study 9386082 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P) - Control group for AP
Number of subjects: 101
Study 8196727 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cyclosporine
Number of subjects: 305
Study 8196727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305
Study 3203055 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg rectally as premedication
Number of subjects: 21
Study 3203055 — intervention group
Group type: COMPARATOR
Intervention: Control group (no diazepam)
Number of subjects: 21
Study 30666023 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based follow-up care (HBFC) intervention administered for 12 months
Number of subjects: 299
Study 30666023 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based follow-up care (HBFC) intervention
Number of subjects: 299
Study 30666023 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 299
Study 28926762 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral micronized progesterone (200mg twice daily)
Number of subjects: 41
Study 28926762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 25556220 — intervention group
Group type: EXPERIMENTAL
Intervention: TSS
Number of subjects: 32
Study 25556220 — intervention group
Group type: EXPERIMENTAL
Intervention: MMA
Number of subjects: 32
Study 25556220 — intervention group
Group type: EXPERIMENTAL
Intervention: D-DLL
Number of subjects: 32
Study 25556220 — intervention group
Group type: EXPERIMENTAL
Intervention: S-DLL
Number of subjects: 32
Study 24498826 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin (0.5 mg/kg/day) + Vitamin E (800 IU/day)
Number of subjects: 60
Study 24498826 — intervention group
Group type: COMPARATOR
Intervention: Isotretinoin (0.5 mg/kg/day) + Cod liver oil (800 IU/day)
Number of subjects: 60
Study 22028471 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents or bare metal stents
Number of subjects: 7162
Study 22028471 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ST
Number of subjects: 7162
Study 19252250 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease modifying anti-rheumatic drugs (DMARDs), specifically methotrexate (MTX) as the anchor drug.
Number of subjects: 0
Study 19252250 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease modifying anti-rheumatic drugs (DMARDs)
Number of subjects: 0
Study 19252250 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 17721621 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aprotinin
Number of subjects: 20
Study 17721621 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aprotinin)
Number of subjects: 20
Study 15982605 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (Prograf)
Number of subjects: 129
Study 15982605 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine microemulsion (Neoral)
Number of subjects: 129
Study 11845649 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-as-Usual (TAU)
Number of subjects: 63
Study 11845649 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive psychotherapy techniques
Number of subjects: 63
Study 11845649 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychodynamic and cognitive techniques
Number of subjects: 63
Study 11845649 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral techniques
Number of subjects: 63
Study 9602764 — intervention group
Group type: EXPERIMENTAL
Intervention: ibuprofen for 3 weeks
Number of subjects: 144
Study 9602764 — intervention group
Group type: EXPERIMENTAL
Intervention: ibuprofen for 1 week and placebo for the next 2 weeks
Number of subjects: 144
Study 9602764 — intervention group
Group type: COMPARATOR
Intervention: placebo for 3 weeks
Number of subjects: 144
Study 8042206 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg GM-1 followed by 100 mg GM-1 daily for 10 days and 100 mg GM-1 intramuscularly for 11-21 days
Number of subjects: 792
Study 8042206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 792
Study 8042206 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-1 (treated within 4 hours)
Number of subjects: 792
Study 8042206 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-1
Number of subjects: 792
Study 3281620 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic-metoprolol combination therapy
Number of subjects: 0
Study 3281620 — intervention group
Group type: COMPARATOR
Intervention: High-dose diuretic therapy (100 to 150 mg/d of hydrochlorothiazide)
Number of subjects: 0
Study 29084488 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy for depression
Number of subjects: 406
Study 28746222 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam 20 mg in 5 mL normal saline (NS)
Number of subjects: 105
Study 28746222 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 105
Study 26135281 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention consisting of multidimensional early detection strategies with age- and interdisciplinary integrated care
Number of subjects: 120
Study 26135281 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 120
Study 23228505 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)
Number of subjects: 58
Study 23228505 — intervention group
Group type: COMPARATOR
Intervention: Thermal balloon ablation (TBA)
Number of subjects: 58
Study 20639712 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acids
Number of subjects: 43
Study 20639712 — intervention group
Group type: EXPERIMENTAL
Intervention: n-6 fatty acids
Number of subjects: 43
Study 20639712 — intervention group
Group type: COMPARATOR
Intervention: saturated fatty acids (placebo)
Number of subjects: 43
Study 18582177 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (0.5 to 3.5 mg/day)
Number of subjects: 38
Study 18582177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 16644278 — intervention group
Group type: EXPERIMENTAL
Intervention: ERP word repetition paradigm
Number of subjects: 11
Study 16644278 — intervention group
Group type: COMPARATOR
Intervention: Normal controls (NC)
Number of subjects: 11
Study 16644278 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild AD group
Number of subjects: 11
Study 16644278 — intervention group
Group type: EXPERIMENTAL
Intervention: Both N400 and P600 potentials
Number of subjects: 11
Study 16644278 — intervention group
Group type: EXPERIMENTAL
Intervention: Group discrimination
Number of subjects: 11
Study 12803353 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized patients (SPs) portraying patient scenarios
Number of subjects: 92
Study 12803353 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized patients (SPs) coding physician performance
Number of subjects: 92
Study 12803353 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized patients (SPs) assessing alcohol consumption and advice against smoking
Number of subjects: 92
Study 10831925 — intervention group
Group type: COMPARATOR
Intervention: Matrix transdermal 17beta‐estradiol patch
Number of subjects: 569
Study 8991327 — intervention group
Group type: EXPERIMENTAL
Intervention: Victimization experiences (e.g., sexual abuse, parental assault, kidnapping)
Number of subjects: 0
Study 8991327 — intervention group
Group type: COMPARATOR
Intervention: Prior psychopathology
Number of subjects: 0
Study 8991327 — intervention group
Group type: COMPARATOR
Intervention: Parent-child relationship problems
Number of subjects: 0
Study 1346182 — intervention group
Group type: EXPERIMENTAL
Intervention: Day unit care
Number of subjects: 54
Study 1346182 — intervention group
Group type: COMPARATOR
Intervention: Control group (established practice)
Number of subjects: 54
Study 6202963 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 12.5 mg t.i.d. for 3 days
Number of subjects: 11
Study 6202963 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 25 mg t.i.d. for 3 days
Number of subjects: 11
Study 6202963 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 50 mg t.i.d. for 3 days
Number of subjects: 11
Study 6202963 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine (all doses)
Number of subjects: 11
Study 29947235 — intervention group
Group type: EXPERIMENTAL
Intervention: miRNA group
Number of subjects: 0
Study 29947235 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 27829449 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral counselling via two 1-h face-to-face sessions and two 15-min telephone calls
Number of subjects: 200
Study 27829449 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care, written PAD management information sheet, and four 15-min telephone calls with general discussion about PAD symptoms and health and wellbeing
Number of subjects: 200
Study 23911555 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 109
Study 23911555 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonic cleansing with MoviPrep
Number of subjects: 109
Study 23911555 — intervention group
Group type: COMPARATOR
Intervention: Healthy Volunteers (Control)
Number of subjects: 109
Study 22727475 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive AVD
Number of subjects: 100
Study 22727475 — intervention group
Group type: COMPARATOR
Intervention: Fixed AVD
Number of subjects: 100
Study 20386133 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometers mounted on each ankle connected to a wearable system for evaluating standing vertical jump.
Number of subjects: 51
Study 20386133 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometers measuring ankle acceleration during countermovement and squat jumps.
Number of subjects: 51
Study 20386133 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak detection algorithm for quantifying flight time from acceleration modulus.
Number of subjects: 51
Study 18317718 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG-RIVM 2x10^8 CFU in six weekly instillations
Number of subjects: 627
Study 18317718 — intervention group
Group type: EXPERIMENTAL
Intervention: MMC 20 mg in six weekly instillations
Number of subjects: 627
Study 18317718 — intervention group
Group type: EXPERIMENTAL
Intervention: MMC 20 mg in six weekly instillations with subsequent monthly instillations for 3 years
Number of subjects: 627
Study 18317718 — intervention group
Group type: EXPERIMENTAL
Intervention: MMC 20 mg instilled weekly six times
Number of subjects: 627
Study 18317718 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant therapy
Number of subjects: 627
Study 16008115 — intervention group
Group type: EXPERIMENTAL
Intervention: Kan Jang (Andrographis paniculata and Acanthopanax senticosus)
Number of subjects: 0
Study 16008115 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginseng (Panax ginseng)
Number of subjects: 0
Study 16008115 — intervention group
Group type: EXPERIMENTAL
Intervention: Valerian (Valeriana officinalis)
Number of subjects: 0
Study 12808486 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (50 mg daily)
Number of subjects: 30
Study 12808486 — intervention group
Group type: COMPARATOR
Intervention: Nebivolol (5 mg daily)
Number of subjects: 30
Study 12808486 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg daily) added after 12 weeks
Number of subjects: 30
Study 10760334 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCA with prolonged perfusion balloon inflation (n = 66)
Number of subjects: 97
Study 10760334 — intervention group
Group type: COMPARATOR
Intervention: Elective stenting (n = 31)
Number of subjects: 97
Study 10760334 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCA (n = 66)
Number of subjects: 97
Study 10760334 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCA alone (n = 66)
Number of subjects: 97
Study 10760334 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover-to-stent arm (n = 15)
Number of subjects: 97
Study 8897119 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX), 0.5 mg at night
Number of subjects: 74
Study 8897119 — intervention group
Group type: COMPARATOR
Intervention: Control group (no DEX)
Number of subjects: 74
Study 1740677 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-field radiotherapy (RT)
Number of subjects: 89
Study 1740677 — intervention group
Group type: COMPARATOR
Intervention: MOPP chemotherapy (CHT)
Number of subjects: 89
Study 31520525 — intervention group
Group type: EXPERIMENTAL
Intervention: Triheptanoin (1 g/kg/day)
Number of subjects: 22
Study 31520525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 30064968 — intervention group
Group type: EXPERIMENTAL
Intervention: Encouragement to try the automated digital health intervention via SMS text messages
Number of subjects: 112
Study 30064968 — intervention group
Group type: COMPARATOR
Intervention: Control group (no encouragement)
Number of subjects: 112
Study 30064968 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group who tried the intervention
Number of subjects: 112
Study 27498095 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 125
Study 27498095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 24495529 — intervention group
Group type: EXPERIMENTAL
Intervention: PIRO scores in ICU transfer group (derivation group)
Number of subjects: 1049
Study 24495529 — intervention group
Group type: EXPERIMENTAL
Intervention: PIRO scores in ICU transfer group (validation group)
Number of subjects: 1049
Study 24495529 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportion of ICU transfer patients by PIRO score ranges (derivation group)
Number of subjects: 1049
Study 24495529 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportion of ICU transfer patients by PIRO score ranges (validation group)
Number of subjects: 1049
Study 24495529 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient mortality by PIRO score ranges (derivation group)
Number of subjects: 1049
Study 24495529 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient mortality by PIRO score ranges (validation group)
Number of subjects: 1049
Study 22796905 — intervention group
Group type: EXPERIMENTAL
Intervention: 13.3 mg/24 h rivastigmine patch
Number of subjects: 567
Study 22796905 — intervention group
Group type: COMPARATOR
Intervention: 9.5 mg/24 h rivastigmine patch
Number of subjects: 567
Study 20951303 — intervention group
Group type: EXPERIMENTAL
Intervention: ProTaper UR
Number of subjects: 60
Study 20951303 — intervention group
Group type: EXPERIMENTAL
Intervention: MTwo R
Number of subjects: 60
Study 20951303 — intervention group
Group type: COMPARATOR
Intervention: Hand instrumentation
Number of subjects: 60
Study 18041917 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher total doses of radiation (1.8-2 Gy)
Number of subjects: 0
Study 18041917 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated regimens (larger daily doses)
Number of subjects: 0
Study 18041917 — intervention group
Group type: COMPARATOR
Intervention: Conventional daily doses (1.8-2 Gy)
Number of subjects: 0
Study 16360360 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 22
Study 12058096 — intervention group
Group type: EXPERIMENTAL
Intervention: STN deep brain stimulation (DBS) ON
Number of subjects: 12
Study 12058096 — intervention group
Group type: COMPARATOR
Intervention: STN deep brain stimulation (DBS) HALF
Number of subjects: 12
Study 12058096 — intervention group
Group type: COMPARATOR
Intervention: STN deep brain stimulation (DBS) OFF
Number of subjects: 12
Study 10965638 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Behavioral Family Intervention (EBFI)
Number of subjects: 305
Study 10965638 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Behavioral Family Intervention (SBFI)
Number of subjects: 305
Study 10965638 — intervention group
Group type: COMPARATOR
Intervention: Self-Directed Behavioral Family Intervention (SDBFI)
Number of subjects: 305
Study 10965638 — intervention group
Group type: COMPARATOR
Intervention: Wait List (WL)
Number of subjects: 305
Study 10965638 — intervention group
Group type: EXPERIMENTAL
Intervention: EBFI and SBFI
Number of subjects: 305
Study 10965638 — intervention group
Group type: EXPERIMENTAL
Intervention: All 3 conditions (EBFI, SBFI, SDBFI)
Number of subjects: 305
Study 8607589 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (30 mg subcutaneously every 12 hours)
Number of subjects: 670
Study 8607589 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (adjusted dose, INR 2.0 to 3.0)
Number of subjects: 670
Study 8607589 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 670
Study 8607589 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 670
Study 1483483 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 14
Study 1483483 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 2990711 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer factor (TF) immunotherapy for 18 months in addition to radiotherapy
Number of subjects: 100
Study 2990711 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 100
Study 30328496 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior-Stabilized (PS) implants
Number of subjects: 100
Study 30328496 — intervention group
Group type: COMPARATOR
Intervention: Medially Congruent (MC) implants
Number of subjects: 100
Study 30092284 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure + TILS
Number of subjects: 0
Study 30092284 — intervention group
Group type: COMPARATOR
Intervention: Exposure + sham TILS
Number of subjects: 0
Study 30092284 — intervention group
Group type: EXPERIMENTAL
Intervention: TILS alone
Number of subjects: 0
Study 30092284 — intervention group
Group type: COMPARATOR
Intervention: Sham TILS alone
Number of subjects: 0
Study 26739268 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-led caregiver-delivered home-based rehabilitation intervention
Number of subjects: 1200
Study 26739268 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 1200
Study 24493185 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee flexion for six hours post-operatively
Number of subjects: 600
Study 24493185 — intervention group
Group type: COMPARATOR
Intervention: Knee flexion for three hours post-operatively
Number of subjects: 600
Study 24493185 — intervention group
Group type: COMPARATOR
Intervention: Knee extension
Number of subjects: 600
Study 22173281 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine XR (37.5 mg/day for 4 days, then 75 mg/day for 6 days)
Number of subjects: 24